Radiolabeled compounds targeting the prostate-specific membrane antigen
US-2024018110-A1 · Jan 18, 2024 · US
US9802886B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9802886-B2 |
| Application number | US-201615348093-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 10, 2016 |
| Priority date | May 15, 2012 |
| Publication date | Oct 31, 2017 |
| Grant date | Oct 31, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to compounds of the formula and to a process for making same and to the use of the products in the solid phase peptide synthesis. The compounds of formula I are versatile peptide intermediates for the solid phase peptide synthesis (SPPS) of peptide drugs which comprise a Glu-fatty alkyl side chain building block attached to a Lys-part of the peptide chain.
Opening claim text (preview).
The invention claimed is: 1. A process for the preparation of compounds of formula I, and enantiomers and salts thereof, wherein: R 1 is hydrogen or an ester protecting group; R 2 is hydrogen; R 3 is hydrogen or an amino protecting group and R 4 is C 12-20 -alkyl; the process comprising: a) coupling the glutamic acid derivative of formula II or a salt thereof with a lysine derivative of formula III wherein R 2′ is an ester protecting group, or a salt thereof to form a compound of the formula Ic; and b) removing the ester protecting group R 2′ to provide the compound of formula I. 2. The process of claim 1 , wherein the ester protecting group is selected from C 1-4 -alkyl, optionally substituted with phenyl, C 2-4 -alkenyl, piperidinyl or dimethylaminoboranyl. 3. The process of claim 1 , wherein R 1 is hydrogen or C 1-4 -alkyl. 4. The process of claim 1 , wherein R 1 is C 1-4 -alkyl. 5. The process of claim 1 , wherein R 1 is hydrogen. 6. The process of claim 1 , wherein R 3 is 9H-fluoren-9-ylmethoxycarbonyl. 7. The process of claim 1 , wherein R 1 is t-butyl. 8. The process of claim 1 , wherein R 4 is C 14-16 -alkyl. 9. The process of claim 1 , wherein R 4 is C 15 -alkyl. 10. The process of claim 1 , wherein R 4 is pentadecyl. 11. The process of claim 1 , wherein R 3 is 9H-fluoren-9-ylmethoxycarbonyl and R 4 is C 15 -alkyl. 12. The process of claim 1 , wherein R 3 is 9H-fluoren-9-ylmethoxycarbonyl and R 4 is pentadecyl. 13. The process of claim 1 , wherein the compound of formula I is a compound of formula Ia 14. The process of claim 1 , wherein the compound of formula I is a compound of formula Ib 15. The process of claim 1 , wherein the coupling of the glutamic acid derivative of formula II with the lysine derivative of formula III is carried out by solid phase synthesis. 16. The process of claim 1 , wherein the coupling of the glutamic acid derivative of formula II with the lysine derivative of formula III is carried out by FMOC solid phase synthesis.
to carbon atoms of hydrocarbon radicals substituted by carboxyl groups · CPC title
by reactions not involving the formation of carbamate groups · CPC title
Fluorenes; Hydrogenated fluorenes · CPC title
and aliphatic · CPC title
Chemical, physical or physico-chemical processes in general; Their relevant apparatus · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.